MRD: Minimal Residual Disease Testing
Monitor residual disease and clonal evolution.
Deep NGS supports MRD assessment and monitoring of clonal evolution over time.
What Is Tested?
Residual Disease
Analyzes cell-free, tumor-derived DNA (ctDNA) in peripheral blood to support MRD assessment.
Relapse Surveillance
Can support relapse surveillance as part of clinical monitoring.
Treatment Response
Helps monitor response after cancer treatment.
When Is Testing Performed?
After surgery
After chemotherapy and/or radiotherapy
For regular cancer monitoring
How Is the Sample Tested?
Blood Sample (ctDNA)
Cell-free, tumor-derived DNA (ctDNA) in a peripheral blood sample is analyzed using Next Generation Sequencing (NGS) to support MRD monitoring. Results do not independently establish recurrence or dictate treatment.
Support MRD Monitoring Through ctDNA
MRD Testing Specifications
Technology
Next Generation Sequencing
Sample
Peripheral blood (ctDNA)
Estimated Turnaround Time
14 working days